CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis

Company Overview

CollPlant Biotechnologies is a regenerative medicine company pioneering the use of recombinant human collagen produced in tobacco plants. By harnessing proprietary plant molecular farming technology, CollPlant develops bioactive, biocompatible collagen-based materials for tissue repair and reconstruction. The company’s innovative platform offers a sustainable source of human collagen that avoids the risks and supply limitations associated with animal-derived products.

The company’s flagship products include Vergenix™ Flowable and Vergenix™STR, advanced collagen matrices designed to support wound healing, soft tissue regeneration and aesthetic procedures. In parallel, CollPlant is advancing a pipeline of cross-linkable bioinks for 3D bioprinting applications in orthopedics, plastic surgery and organ engineering. These bioinks are formulated to promote cell attachment and tissue maturation, positioning CollPlant at the forefront of biofabrication technologies.

Founded in 2007 and headquartered in Ness Ziona, Israel, CollPlant maintains operations in the United States to serve global markets. The company collaborates with leading medical device firms, pharmaceutical partners and research institutions to accelerate commercialization of its collagen-based solutions. Strategic alliances span Europe, Asia and North America, reflecting CollPlant’s commitment to addressing unmet clinical needs worldwide.

Under the leadership of Chief Executive Officer Yehiel Tal and co-founder and Chief Science Officer Morad Jaber, CollPlant combines scientific expertise with industrial-scale manufacturing capabilities. The management team’s experience in biotechnology and regenerative medicine supports the company’s long-term vision of transforming patient care through scalable, high-performance collagen products.

Key Stats

• Today's Range: $1.79 to $2.05
• 50-Day Range: $1.35 to $4.54
• 52-Week Range: $1.31 to $5.45
• Volume: 94,010 shs
• Average Volume: 37,975 shs
• Market Capitalization: $25.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Buy

CollPlant Biotechnologies Stock Analysis - MarketRank™

CollPlant Biotechnologies scored higher than 36% of companies evaluated by MarketBeat, and ranked 601st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

CollPlant Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.44) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CollPlant Biotechnologies is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CollPlant Biotechnologies is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CollPlant Biotechnologies has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.88% of the float of CollPlant Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

CollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CollPlant Biotechnologies has recently increased by 9.21%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CollPlant Biotechnologies does not currently pay a dividend.

Dividend Growth

CollPlant Biotechnologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.88% of the float of CollPlant Biotechnologies has been sold short.

Short Interest Ratio / Days to Cover

CollPlant Biotechnologies has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CollPlant Biotechnologies has recently increased by 9.21%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for CollPlant Biotechnologies this week, compared to 0 articles on an average week.

Search Interest

Only 2 people have searched for CLGN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.60% of the stock of CollPlant Biotechnologies is held by insiders.

Percentage Held by Institutions

Only 21.69% of the stock of CollPlant Biotechnologies is held by institutions.

CLGN Stock Analysis - Frequently Asked Questions

How have CLGN shares performed this year?

CollPlant Biotechnologies' stock was trading at $3.60 on January 1st, 2025. Since then, CLGN stock has decreased by 43.6% and is now trading at $2.03.

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) announced its quarterly earnings results on Wednesday, June, 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.24. The company earned $2.06 million during the quarter, compared to analysts' expectations of $9.76 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 87.33% and a negative net margin of 560.92%.

When did CollPlant Biotechnologies IPO?

CollPlant Biotechnologies (CLGN) raised $22 million in an IPO on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CollPlant Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA).

Company Calendar

• Last Earnings: 6/04/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CLGN
• CIK: 1631487
• Web: www.collplant.com
• Phone: 972732325600
• Fax: 972-73-232-5602
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CollPlant Biotechnologies: $11.50
• High Price Target: $12.00
• Low Price Target: $11.00
• Potential Upside/Downside: +466.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.61 million
• Net Margins: -560.92%
• Pretax Margin: -560.92%
• Return on Equity: -87.33%
• Return on Assets: -65.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.48
• Quick Ratio: 4.23

Sales & Book Value

• Annual Sales: $510 thousand
• Price / Sales: 50.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.18 per share
• Price / Book: 1.72

Miscellaneous

• Outstanding Shares: 12,720,000
• Free Float: 11,495,000
• Market Cap: $25.82 million
• Optionable: Optionable
• Beta: 1.33